Concord Biotech Ltd: Fermenting Profits or Just Overcooked Hype?
1. At a Glance
Concord Biotech is India’s fermentation pharma ninja, pumping out high-margin APIs like immunosuppressants and oncology drugs. With 42% EBITDA margins, a 29% ROCE, and a fresh US acquisition, the ₹18,865 Cr beast is either pharma royalty… or priced like it.
2. Introduction with Hook
Imagine a biopharma startup from the 80s, buried in Petri dishes, suddenly pulling off a $1,500 Mn US buyout, clearing a USFDA audit, and delivering 44% OPM.
FY25 Sales: ₹1,200 Cr
FY25 PAT: ₹372 Cr
ROCE: 30% | PE: 50x
Concord isn’t curing cancer. But it might be curing your boring pharma portfolio.
3. Business Model (WTF Do They Even Do?)
Concord = specialist fermentation-driven API + injectable formulations:
Core verticals:
Immunosuppressants (e.g. Tacrolimus, Sirolimus)
Oncology APIs
Anti-infectives
Manufacturing facilities: India-based, global reach
